| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[12] Enoxaparin, SC (dosing for treatment of VTE): National Department of Health: Affordable Medicines, EDP-Adult Hospital Level. Medicine Review LMWH vs. UFH for the prophylaxis and treatment of venous thromboembolism and acute coronary syndromes – Appendix A, April 2018. http://www.health.gov.za/
Low molecular weight heparin (dosing for treatment of VTE): Bhutia S, Wong PF. Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane database Syst Rev. 2013 Jul;(7):CD003074. https://www.ncbi.nlm.nih.gov/pubmed/23857562